文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

重组人白细胞介素-7在重症COVID-19患者中体外逆转T细胞耗竭

Recombinant human interleukin-7 reverses T cell exhaustion ex vivo in critically ill COVID-19 patients.
PubMed 文献 · Ann Intensive Care · 2022-03-05
一句话结论重症COVID-19患者入住ICU时存在深度T细胞耗竭,体外给予rhIL-7可显著改善T细胞增殖和IFN-γ产生。

该研究纳入入住ICU的COVID-19患者,于入ICU时和20天后采集外周血单个核细胞,用NanoString技术评估转录组,流式细胞术检测抑制性免疫检查点表达,并在体外刺激后评估T淋巴细胞增殖和IFN-γ产生。结果显示,患者入ICU时明显淋巴细胞减少,单核细胞转录组呈抑制性特征且T细胞激活通路受损,CD4+和CD8+ T细胞上PD-1、PD-L1、CTLA-4和TIM-3过表达,T细胞增殖和IFN-γ产生明显受损,这些T细胞耗竭特征在入ICU时更明显、随时间缓解。体外给予rhIL-7可显著改善COVID-19患者T细胞增殖和IFN-γ产生。作者认为这些结果加深了对重症COVID-19病理生理的理解,并开辟了免疫调节治疗的新途径,但需确定临床启动时机和患者选择标志物以证实体外结果。

要点

  • 重症COVID-19患者入ICU时存在明显淋巴细胞减少,外周血单个核细胞转录组呈抑制性特征,T细胞激活通路受损。
  • CD4+和CD8+ T细胞上共抑制分子PD-1、PD-L1、CTLA-4和TIM-3过表达,T细胞增殖和IFN-γ产生明显受损,符合T细胞耗竭状态。
  • 上述T细胞耗竭特征在入ICU时更明显,入住20天后减轻。
  • 体外给予rhIL-7可显著改善COVID-19患者T细胞增殖和IFN-γ产生。
  • 作者认为需确定临床启动免疫辅助治疗的适当时机和选择患者的合适标志物,以证实体外结果。

适用人群与场景

  • 入住ICU的COVID-19患者,于入ICU时和20天后采集外周血单个核细胞。

研究设计与关键结果

  • 研究类型为体外实验,纳入入住ICU的COVID-19患者,于入ICU时和20天后采集外周血单个核细胞。
  • 患者入ICU时明显淋巴细胞减少;单核细胞转录组呈抑制性特征,以T细胞激活通路受损为主;CD4+和CD8+ T细胞上PD-1、PD-L1、CTLA-4和TIM-3过表达。
  • 入ICU时采集的样本中CD4+和CD8+ T细胞增殖和IFN-γ产生明显受损,这些T细胞耗竭特征在入ICU时更明显,随时间缓解。
  • 体外给予rhIL-7可显著改善COVID-19患者T细胞增殖和IFN-γ产生。

证据类型、等级与局限

  • 证据类型:体外实验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,该结果加深了对重症COVID-19病理生理的理解,并开辟了基于免疫调节方法治疗此类危重患者的新治疗途径。
  • 作者认为,需确定临床启动此类免疫辅助治疗的适当时机以及选择患者的合适标志物,以证实目前描述的体外结果。

指南或共识出处

  • Trial registration ClinicalTrials.gov identifier: NCT04392401,注册日期2020年5月18日。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Lymphopenia is a hallmark of severe coronavirus disease 19 (COVID-19). Similar alterations have been described in bacterial sepsis and therapeutic strategies targeting T cell function such as recombinant human interleukin 7 (rhIL-7) have been proposed in this clinical context. As COVID-19 is a viral sepsis, the objectives of this study were to characterize T lymphocyte response over time in severe COVID-19 patients and to assess the effect of ex vivo administration of rhIL-7.

RESULTS: Peripheral blood mononuclear cells from COVID-19 patients hospitalized in intensive care unit (ICU) were collected at admission and after 20 days. Transcriptomic profile was evaluated through NanoString technology. Inhibitory immune checkpoints expressions were determined by flow cytometry. T lymphocyte proliferation and IFN-γ production were evaluated after ex vivo stimulation in the presence or not of rhIL-7. COVID-19 ICU patients were markedly lymphopenic at admission. Mononuclear cells presented with inhibited transcriptomic profile prevalently with impaired T cell activation pathways. CD4 + and CD8 + T cells presented with over-expression of co-inhibitory molecules PD-1, PD-L1, CTLA-4 and TIM-3. CD4 + and CD8 + T cell proliferation and IFN-γ production were markedly altered in samples collected at ICU admission. These alterations, characteristic of a T cell exhaustion state, were more pronounced at ICU admission and alleviated over time. Treatment with rhIL-7 ex vivo significantly improved both T cell proliferation and IFN-γ production in cells from COVID-19 patients.

CONCLUSIONS: Severe COVID-19 patients present with features of profound T cell exhaustion upon ICU admission which can be reversed ex vivo by rhIL-7. These results reinforce our understanding of severe COVID-19 pathophysiology and opens novel therapeutic avenues to treat such critically ill patients based of immunomodulation approaches. Defining the appropriate timing for initiating such immune-adjuvant therapy in clinical setting and the pertinent markers for a careful selection of patients are now warranted to confirm the ex vivo results described so far. Trial registration ClinicalTrials.gov identifier: NCT04392401 Registered 18 May 2020, http:// clinicaltrials.gov/ct2/show/NCT04392401.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Bidar F, Hamada S, Gossez M, et al. Recombinant human interleukin-7 reverses T cell exhaustion ex vivo in critically ill COVID-19 patients. Ann Intensive Care. 2022. PMID: 35246776. doi:10.1186/s13613-022-00982-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。